Strs Ohio Sells 14,796 Shares of DexCom, Inc. $DXCM

Strs Ohio reduced its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 6.2% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 224,150 shares of the medical device company’s stock after selling 14,796 shares during the period. Strs Ohio owned about 0.06% of DexCom worth $15,083,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Brighton Jones LLC raised its position in DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company’s stock valued at $1,290,000 after buying an additional 11,946 shares during the last quarter. Integrated Wealth Concepts LLC boosted its holdings in DexCom by 6.3% during the 1st quarter. Integrated Wealth Concepts LLC now owns 3,329 shares of the medical device company’s stock worth $227,000 after acquiring an additional 196 shares during the last quarter. Empowered Funds LLC grew its stake in shares of DexCom by 5.4% in the 1st quarter. Empowered Funds LLC now owns 8,446 shares of the medical device company’s stock worth $577,000 after acquiring an additional 436 shares in the last quarter. Focus Partners Wealth raised its holdings in shares of DexCom by 13.2% in the first quarter. Focus Partners Wealth now owns 7,218 shares of the medical device company’s stock valued at $493,000 after purchasing an additional 841 shares during the last quarter. Finally, Farther Finance Advisors LLC raised its holdings in shares of DexCom by 18.7% in the second quarter. Farther Finance Advisors LLC now owns 3,680 shares of the medical device company’s stock valued at $321,000 after purchasing an additional 580 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DXCM has been the topic of several analyst reports. Leerink Partners restated an “outperform” rating and set a $92.00 price target on shares of DexCom in a report on Tuesday, December 16th. The Goldman Sachs Group dropped their target price on shares of DexCom from $104.00 to $89.00 and set a “buy” rating on the stock in a research report on Wednesday, October 1st. Canaccord Genuity Group set a $99.00 target price on DexCom and gave the company a “buy” rating in a report on Friday, October 31st. Sanford C. Bernstein reaffirmed an “outperform” rating and set a $86.00 price target (up from $84.00) on shares of DexCom in a research report on Friday, January 9th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of DexCom in a report on Monday, January 12th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $86.30.

Insiders Place Their Bets

In other news, Director Richard Alexander Collins sold 3,948 shares of DexCom stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $55.17, for a total value of $217,811.16. Following the completion of the transaction, the director owned 37,994 shares in the company, valued at $2,096,128.98. This trade represents a 9.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Jacob Steven Leach purchased 18,200 shares of the stock in a transaction dated Monday, November 10th. The stock was acquired at an average cost of $55.04 per share, for a total transaction of $1,001,728.00. Following the transaction, the chief operating officer owned 331,697 shares of the company’s stock, valued at approximately $18,256,602.88. This trade represents a 5.81% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders sold 7,866 shares of company stock worth $448,177 over the last quarter. 0.32% of the stock is currently owned by company insiders.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $72.86 on Monday. The company has a current ratio of 1.56, a quick ratio of 1.38 and a debt-to-equity ratio of 0.45. The stock has a fifty day simple moving average of $66.41 and a two-hundred day simple moving average of $71.06. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $93.25. The firm has a market cap of $28.42 billion, a price-to-earnings ratio of 40.48, a price-to-earnings-growth ratio of 1.31 and a beta of 1.48.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. The firm had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.18 billion. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The business’s revenue for the quarter was up 21.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.45 EPS. Analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.